Medidata Solutions (NASDAQ:MDSO) had its price objective cut by research analysts at Morgan Stanley from $86.00 to $79.00 in a research note issued on Friday. The firm currently has an “overweight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 21.59% from the company’s previous close.

A number of other equities analysts have also recently issued reports on MDSO. Wells Fargo & Co cut their target price on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating on the stock in a report on Friday, October 27th. SunTrust Banks reiterated a “buy” rating and issued a $92.00 target price on shares of Medidata Solutions in a report on Friday, October 27th. Royal Bank of Canada reiterated a “hold” rating and issued a $80.00 target price on shares of Medidata Solutions in a report on Friday, October 27th. Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. Finally, Dougherty & Co started coverage on Medidata Solutions in a report on Thursday, November 2nd. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $83.00.

Shares of Medidata Solutions (NASDAQ:MDSO) opened at $64.97 on Friday. The company has a market cap of $3,660.24, a P/E ratio of 87.80, a PEG ratio of 3.24 and a beta of 1.58. Medidata Solutions has a 52-week low of $54.36 and a 52-week high of $85.92. The company has a current ratio of 1.50, a quick ratio of 3.37 and a debt-to-equity ratio of 0.20.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.31 by $0.10. Medidata Solutions had a net margin of 8.14% and a return on equity of 11.59%. The company had revenue of $141.20 million during the quarter, compared to the consensus estimate of $140.65 million. During the same quarter last year, the firm posted $0.33 EPS. The company’s quarterly revenue was up 13.4% on a year-over-year basis. research analysts expect that Medidata Solutions will post 0.93 earnings per share for the current year.

In other Medidata Solutions news, CFO Rouven Bergmann sold 2,000 shares of the firm’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $65.40, for a total transaction of $130,800.00. Following the transaction, the chief financial officer now directly owns 91,775 shares in the company, valued at approximately $6,002,085. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael L. Capone sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $66.33, for a total value of $331,650.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,010 shares of company stock worth $1,962,206. Company insiders own 5.80% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Royce & Associates LP lifted its stake in Medidata Solutions by 45.6% during the 4th quarter. Royce & Associates LP now owns 416,017 shares of the company’s stock valued at $26,363,000 after acquiring an additional 130,352 shares in the last quarter. UBS Asset Management Americas Inc. lifted its stake in Medidata Solutions by 4.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 37,821 shares of the company’s stock valued at $2,397,000 after acquiring an additional 1,639 shares in the last quarter. Schroder Investment Management Group bought a new position in Medidata Solutions during the 4th quarter valued at $626,000. Polen Capital Management LLC lifted its stake in Medidata Solutions by 77.0% during the 4th quarter. Polen Capital Management LLC now owns 4,640 shares of the company’s stock valued at $294,000 after acquiring an additional 2,018 shares in the last quarter. Finally, Arizona State Retirement System lifted its stake in Medidata Solutions by 27.1% during the 4th quarter. Arizona State Retirement System now owns 42,079 shares of the company’s stock valued at $2,667,000 after acquiring an additional 8,965 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Medidata Solutions (MDSO) Given New $79.00 Price Target at Morgan Stanley” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/11/medidata-solutions-mdso-given-new-79-00-price-target-at-morgan-stanley.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.